Abstract

IntroductionGenomic variability limits the efficacy of breast cancer therapy. To simplify the study of the molecular complexity of breast cancer, researchers have used mouse mammary tumor models. However, the degree to which mouse models model human breast cancer and are reflective of the human heterogeneity has yet to be demonstrated with gene expression studies on a large scale.MethodsTo this end, we have built a database consisting of 1,172 mouse mammary tumor samples from 26 different major oncogenic mouse mammary tumor models.ResultsIn this dataset we identified heterogeneity within mouse models and noted a surprising amount of interrelatedness between models, despite differences in the tumor initiating oncogene. Making comparisons between models, we identified differentially expressed genes with alteration correlating with initiating events in each model. Using annotation tools, we identified transcription factors with a high likelihood of activity within these models. Gene signatures predicted activation of major cell signaling pathways in each model, predictions that correlated with previous genetic studies. Finally, we noted relationships between mouse models and human breast cancer at both the level of gene expression and predicted signal pathway activity. Importantly, we identified individual mouse models that recapitulate human breast cancer heterogeneity at the level of gene expression.ConclusionsThis work underscores the importance of fully characterizing mouse tumor biology at molecular, histological and genomic levels before a valid comparison to human breast cancer may be drawn and provides an important bioinformatic resource.

Highlights

  • Genomic variability limits the efficacy of breast cancer therapy

  • With the identification of human epithelial growth factor receptor 2 (HER2) amplification in human breast cancer [5,6], the observation that mammary tumor virus (MMTV) driven expression of the activated rat form of HER2 (NeuNT) resulted in breast cancer reinforced the importance of HER2 as a driving oncogene [7]

  • We measured the non-biological variance between gene expression studies and batch correction with principle components analysis (PCA) (Additional file 5A-D)

Read more

Summary

Introduction

Genomic variability limits the efficacy of breast cancer therapy. To simplify the study of the molecular complexity of breast cancer, researchers have used mouse mammary tumor models. The Cancer Genome Atlas (TCGA) and the Encyclopedia of DNA Elements (ENCODE) projects show remarkable variability in genetic alterations beyond gene expression both across and within subtypes of human breast cancer. Together these genomic analyses demonstrate the complex nature of human breast cancer. Mouse models of breast cancer have employed various methods of initiation, including mouse mammary tumor virus (MMTV) infection, chemical mutagenesis and genetically engineered mice (GEM). This pioneering work identified and tested the role of many oncogenes in breast cancer. Models have been refined to include tissue specific activation resulting in gene amplification, analogous to human HER2+ breast cancer [8], as well as temporal control where transgene expression can be activated or inactivated [9]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call